Proactive Investors - Run By Investors For Investors

Arix Bioscience portfolio company Autolus Therapeutics raises US$109mln

The total of US$109mln is more than Autolus had originally set out to raise from the market
cancer cells
Arix’s 7.5% stake is currently valued at US$94mln (£72mln)

Autolus Therapeutics PLC (NASDAQ:AUTL), a portfolio company of biotech investor Arix Bioscience PLC (LON:ARIX), has raised more than expected from its recent public offering.

Autolus, which is developing next-gen cancer immunotherapies, had originally set out to raise US$100.8mln through the issue of 4.2mln American Depositary Shares (ADS) at US$24.00 apiece.

READ: Arix to invest another US$5mln in Autolus

But it ended up issuing 4.83mln ADS at the same price to raise US$109.0mln.

As part of the offering, Arix agreed to invest US$5mln, keeping its stake in Autolus at 7.5%, which is currently valued at US$94mln (£72mln).

Speaking last week, Arix chief executive Joe Anderson said: “Our investment in Autolus demonstrates our strategy to build world-leading biotech companies through the provision of flexible, long term capital.

“We believe Autolus is at the forefront of a revolution in cancer treatment and that its innovative approach to T-cell programming has the potential to offer life-changing therapies for patients.”

View full ARIX profile View Profile

Arix Bioscience PLC Timeline

Related Articles

An illustration of Ozop's BLIF technique
March 30 2019
A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology
man pointing to brain
April 25 2019
Brain Scientific’s EEG technology is far cheaper and less bulky than a traditional EEG system, but provides EEG tracings of the same quality
Weight loss
January 07 2019
A deal with Indian firm Zeon Lifesciences in January is the ninth deal the firm has secured for the weight loss product

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use